Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is making significant strides in the development of its proprietary multiple sclerosis therapy candidate, LUCID-MS, which targets demyelination and aims to protect or restore myelin integrity. The company recently reported that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile and that the therapy was generally well tolerated, supporting its advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.
The potential significance of LUCID-MS lies in its differentiated, potentially first-in-class approach. Unlike many existing therapies that rely primarily on immune modulation, LUCID-MS aims to directly address myelin loss and neurodegeneration. This could offer a new avenue for treating multiple sclerosis, a chronic neurodegenerative disease that affects millions worldwide. The company is also strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists.
The advancement of LUCID-MS into Phase 2 trials represents a critical milestone for Quantum BioPharma and the multiple sclerosis community. If successful, the therapy could provide a novel treatment option that targets the underlying mechanisms of the disease rather than just managing symptoms. For the industry, this could signal a shift toward therapies that focus on myelin repair and neuroprotection, potentially improving outcomes for patients.
Quantum BioPharma's broader pipeline includes drug candidates for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Additionally, the company invented unbuzzd and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity.
The latest news and updates relating to Quantum BioPharma are available in the company's newsroom at https://ibn.fm/QNTM. The full article discussing LUCID-MS can be viewed at https://ibn.fm/AUhNl. Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's SEC filings, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
